Current management of obsessive and phobic states

Serena Goljevscek1, Livia A Carvalho21Psychiatric Clinic, University of Udine, Udine, Italy; 2Health Science Research Centre, Department of Life Sciences, Roehampton University, London, UKAbstract: Obsessional states show an average point prevalence of 1%–3% and a lifetime prevalence o...

Full description

Bibliographic Details
Main Authors: Goljevscek S, Carvalho LA
Format: Article
Language:English
Published: Dove Medical Press 2011-09-01
Series:Neuropsychiatric Disease and Treatment
Online Access:http://www.dovepress.com/current-management-of-obsessive-and-phobic-states-a8394
id doaj-4feee98557d946e983ad81083c2dec2f
record_format Article
spelling doaj-4feee98557d946e983ad81083c2dec2f2020-11-24T22:17:57ZengDove Medical PressNeuropsychiatric Disease and Treatment1176-63281178-20212011-09-012011Issue 1599610Current management of obsessive and phobic statesGoljevscek SCarvalho LASerena Goljevscek1, Livia A Carvalho21Psychiatric Clinic, University of Udine, Udine, Italy; 2Health Science Research Centre, Department of Life Sciences, Roehampton University, London, UKAbstract: Obsessional states show an average point prevalence of 1%–3% and a lifetime prevalence of 2%–2.5%. Most treatment-seeking patients with obsessions continue to experience significant symptoms after 2 years of prospective follow-up. A significant burden of impairment, distress, and comorbidity characterize the course of the illness, leading to an increased need for a better understanding of the nature and management of this condition. This review aims to give a representation of the current pharmacological and psychotherapeutic strategies used in the treatment of obsessive-compulsive disorder. Antidepressants (clomipramine and selective serotonin reuptake inhibitors) are generally the first-line choice used to handle obsessional states, showing good response rates and long-term positive outcomes. About 40% of patients fail to respond to selective serotonin reuptake inhibitors. So far, additional pharmacological treatment strategies have been shown to be effective, ie, administration of high doses of selective serotonin reuptake inhibitors, as well as combinations of different drugs, such as dopamine antagonists, are considered efficacious and well tolerated strategies in terms of symptom remission and side effects. Psychotherapy also plays an important role in the management of obsessive-compulsive disorder, being effective for a wide range of symptoms, and many studies have assessed its long-term efficacy, especially when added to appropriate pharmacotherapy. In this paper, we also give a description of the clinical and psychological features likely to characterize patients refractory to treatment for this illness, with the aim of highlighting the need for greater attention to more patient-oriented management of the disease.Keywords: obsessive-compulsive disorder, phobic disorder, treatmenthttp://www.dovepress.com/current-management-of-obsessive-and-phobic-states-a8394
collection DOAJ
language English
format Article
sources DOAJ
author Goljevscek S
Carvalho LA
spellingShingle Goljevscek S
Carvalho LA
Current management of obsessive and phobic states
Neuropsychiatric Disease and Treatment
author_facet Goljevscek S
Carvalho LA
author_sort Goljevscek S
title Current management of obsessive and phobic states
title_short Current management of obsessive and phobic states
title_full Current management of obsessive and phobic states
title_fullStr Current management of obsessive and phobic states
title_full_unstemmed Current management of obsessive and phobic states
title_sort current management of obsessive and phobic states
publisher Dove Medical Press
series Neuropsychiatric Disease and Treatment
issn 1176-6328
1178-2021
publishDate 2011-09-01
description Serena Goljevscek1, Livia A Carvalho21Psychiatric Clinic, University of Udine, Udine, Italy; 2Health Science Research Centre, Department of Life Sciences, Roehampton University, London, UKAbstract: Obsessional states show an average point prevalence of 1%–3% and a lifetime prevalence of 2%–2.5%. Most treatment-seeking patients with obsessions continue to experience significant symptoms after 2 years of prospective follow-up. A significant burden of impairment, distress, and comorbidity characterize the course of the illness, leading to an increased need for a better understanding of the nature and management of this condition. This review aims to give a representation of the current pharmacological and psychotherapeutic strategies used in the treatment of obsessive-compulsive disorder. Antidepressants (clomipramine and selective serotonin reuptake inhibitors) are generally the first-line choice used to handle obsessional states, showing good response rates and long-term positive outcomes. About 40% of patients fail to respond to selective serotonin reuptake inhibitors. So far, additional pharmacological treatment strategies have been shown to be effective, ie, administration of high doses of selective serotonin reuptake inhibitors, as well as combinations of different drugs, such as dopamine antagonists, are considered efficacious and well tolerated strategies in terms of symptom remission and side effects. Psychotherapy also plays an important role in the management of obsessive-compulsive disorder, being effective for a wide range of symptoms, and many studies have assessed its long-term efficacy, especially when added to appropriate pharmacotherapy. In this paper, we also give a description of the clinical and psychological features likely to characterize patients refractory to treatment for this illness, with the aim of highlighting the need for greater attention to more patient-oriented management of the disease.Keywords: obsessive-compulsive disorder, phobic disorder, treatment
url http://www.dovepress.com/current-management-of-obsessive-and-phobic-states-a8394
work_keys_str_mv AT goljevsceks currentmanagementofobsessiveandphobicstates
AT carvalhola currentmanagementofobsessiveandphobicstates
_version_ 1725783741433905152